SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
巫马凌旋
Lv3
220 积分
2022-04-26 加入
最近求助
最近应助
互助留言
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
28天前
已完结
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
30天前
已完结
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial
1个月前
已完结
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
1个月前
已完结
Cancer incidence and mortality in China, 2022
1个月前
已完结
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
1个月前
已完结
Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer
1个月前
已完结
Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response
1个月前
已完结
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
1个月前
已完结
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
1个月前
已完结
没有进行任何应助
感谢
28天前
感谢
30天前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论